Nature Communications

Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial

2025-05-16

Full text

DOI https://doi.org/10.1038/s41467-025-59744-9